RECORD // Company

Jasper Therapeutics, Inc.

Formerly: Amplitude Healthcare Acquisition Corp

Built 2026-11-22T01:26:58Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Jasper Therapeutics, Inc. · Ctgov · same registered legal name as 'Jasper Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • JASPER THERAPEUTICS · Epa echo · exact name match to 'Jasper Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • JASPER THERAPEUTICS · Epa echo · exact name match to 'Jasper Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120161

ItemValuePeriodFormFiledAccessionReport
Revenue$8,000,0003 months ended 2026-09-3010-Q2026-11-160001213900-26-1201612026-11-22 01:26 UTCReport an error
Net income (loss)$-144,455,0003 months ended 2026-09-3010-Q2026-11-160001213900-26-1201612026-11-22 01:26 UTCReport an error
Cash and cash equivalents$135,349,000at 2026-09-3010-Q2026-11-160001213900-26-1201612026-11-22 01:26 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001788028
Ticker
JSPR
EIN
842984849
CUSIP
471871301
Record ID
sx:sec:0001788028

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

22 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
Business address2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 940652026-11-16SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-75,801,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 01:26 UTCReport an error
Total assets (at 2025-12-31)$35,779,0002025-12-3110-K, XBRL Assets2026-11-22 01:26 UTCReport an error
Stockholders' equity (at 2025-12-31)$4,151,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 01:26 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$28,692,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 01:26 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-77,161,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 01:26 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,235,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 01:26 UTCReport an error
Form D total offering amount (D filed 2026-08-05)$131,999,6112026-08-05D2026-11-22 01:26 UTCReport an error
Form D total amount sold (D filed 2026-08-05)$131,999,6112026-08-05D2026-11-22 01:26 UTCReport an error
Form D industry groupBiotechnology2026-08-05D2026-11-22 01:26 UTCReport an error
Form D revenue rangeDecline to Disclose2026-08-05D2026-11-22 01:26 UTCReport an error
Form D date of first sale2026-07-212026-08-05D2026-11-22 01:26 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-16)On November 16, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2026 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall…2026-11-16SEC EDGAR 8-K 0001213900-26-120141 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-13)On November 13, 2026, Jasper Therapeutics, Inc. (the “Company”) convened and then determined to adjourn, without conducting any business, a special meeting of stockholders (the “Special Meeting”) because the Company did not have a sufficient number of shares of the Company’s voting common stock present in person, by remote communication or represented by proxy at the Special Meeting to constitute a quorum. The adjourned Special Meeting will reconvene on Tuesday, December 1, 2026, at 10:00 a.m. Pacific Time, virtually via live audio webcast at https://www.cstproxy.com/jaspertherapeutics/sms2026. The close of business on September 28, 2026 will continue to be the record date for the…2026-11-13SEC EDGAR 8-K 0001213900-26-119785 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 3.03, Material Modification to Rights of Security Holders (filed 2026-11-04)To the extent required by2026-11-04SEC EDGAR 8-K 0001213900-26-115751 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change (filed 2026-11-04)in Fiscal Year. On November 2, 2026, Jasper Therapeutics, Inc. (the “Company”) filed a Certificate of Third Amendment to its Second Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware to effect a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s voting common stock, par value $0.0001 per share (“Common Stock”). As previously disclosed, at the Company’s special meeting of stockholders held on September 30, 2026, the stockholders of the Company approved the Certificate of Amendment to effect, in the sole discretion of the Board of Directors of the Company (the…2026-11-04SEC EDGAR 8-K 0001213900-26-115751 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)On November 4, 2026, the Company issued a press release with respect to the Reverse Stock Split. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”). The information contained in this Item 7.01 of this Current Report, including Exhibit 99.1 hereto, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether…2026-11-04SEC EDGAR 8-K 0001213900-26-115751 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.